Celldex Therapeutics (CLDX) Cash & Equivalents Growth (1y) (2011 - 2026)
Celldex Therapeutics (CLDX) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 71.81% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 84.98% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 10.29% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 28.50% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 53.39% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -57.58% |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 105.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 105.93% |
| Mar 31, 2026 | 108.50% |
| Dec 31, 2025 | 1.82% |
| Sep 30, 2025 | -0.99% |
| Jun 30, 2025 | -46.08% |
| Mar 31, 2025 | -85.11% |
| Dec 31, 2024 | -18.55% |
| Sep 30, 2024 | 72.23% |
| Jun 30, 2024 | 51.43% |
| Mar 31, 2024 | 112.62% |
| Dec 31, 2023 | 18.30% |
| Sep 30, 2023 | 13.73% |
| Jun 30, 2023 | -0.62% |
| Mar 31, 2023 | 113.98% |
| Dec 31, 2022 | -24.82% |
| Sep 30, 2022 | -74.26% |
| Jun 30, 2022 | -34.63% |
| Mar 31, 2022 | -63.51% |
| Dec 31, 2021 | -10.71% |
| Sep 30, 2021 | 297.69% |